Literature DB >> 28560695

High-Tech Drugs in Creaky Formulations.

Maikel Herbrink1, Bastiaan Nuijen2, Jan H M Schellens2,3, Jos H Beijnen2,3.   

Abstract

Recent literature reviews and registration documents covering novel Signal Transduction Inhibitors in the treatment of cancer paint a picture of inefficiency and variability, where formulation improvements could be valuable. In this article, we discuss apparent drug design flaws as we impose the current standard formulation practice.

Entities:  

Keywords:  anticancer drugs; biopharmaceutics; formulation; pharmaceutics

Mesh：

Substances：

Year:  2017        PMID： 28560695     DOI： 10.1007/s11095-017-2185-4

Source DB:  PubMed          Journal:  Pharm Res        ISSN： 0724-8741            Impact factor:   4.200


  9 in total

1.  Factors affecting intrasubject variability of PK exposure: absolute oral bioavailability and acidic nature of drugs.

Authors:  Masahiko Sato; Mamoru Narukawa
Journal:  Int J Clin Pharmacol Ther       Date:  2015-11       Impact factor: 1.366

Review 2.  Variability in bioavailability of small molecular tyrosine kinase inhibitors.

Authors:  Maikel Herbrink; Bastiaan Nuijen; Jan H M Schellens; Jos H Beijnen
Journal:  Cancer Treat Rev       Date:  2015-03-20       Impact factor: 12.111

3.  Without therapeutic drug monitoring, there is no personalized cancer care.

Authors:  J H Beumer
Journal:  Clin Pharmacol Ther       Date:  2013-03       Impact factor: 6.875

Review 4.  Determining the optimal dose in the development of anticancer agents.

Authors:  Ron H J Mathijssen; Alex Sparreboom; Jaap Verweij
Journal:  Nat Rev Clin Oncol       Date:  2014-03-25       Impact factor: 66.675

Review 5.  Effect of food and acid-reducing agents on the absorption of oral targeted therapies in solid tumors.

Authors:  Annelieke E C A B Willemsen; Floor J E Lubberman; Jolien Tol; Winald R Gerritsen; Carla M L van Herpen; Nielka P van Erp
Journal:  Drug Discov Today       Date:  2016-03-17       Impact factor: 7.851

Review 6.  Inherent formulation issues of kinase inhibitors.

Authors:  M Herbrink; J H M Schellens; J H Beijnen; B Nuijen
Journal:  J Control Release       Date:  2016-08-28       Impact factor: 9.776

7.  Influence of the Acidic Beverage Cola on the Absorption of Erlotinib in Patients With Non-Small-Cell Lung Cancer.

Authors:  Roelof W F van Leeuwen; Robert Peric; Koen G A M Hussaarts; Emma Kienhuis; Nikki S IJzerman; Peter de Bruijn; Cor van der Leest; Henk Codrington; Jeroen S Kloover; Bronno van der Holt; Joachim G Aerts; Teun van Gelder; Ron H J Mathijssen
Journal:  J Clin Oncol       Date:  2016-02-08       Impact factor: 44.544

Review 8.  Pharmacokinetic Aspects of Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors.

Authors:  Beatrix Wulkersdorfer; Markus Zeitlinger; Monika Schmid
Journal:  Clin Pharmacokinet       Date:  2016-01       Impact factor: 6.447

9.  Improved human bioavailability of vemurafenib, a practically insoluble drug, using an amorphous polymer-stabilized solid dispersion prepared by a solvent-controlled coprecipitation process.

Authors:  Navnit Shah; Raman M Iyer; Hans-Juergen Mair; Duk Soon Choi; Hung Tian; Ralph Diodone; Karsten Fähnrich; Anni Pabst-Ravot; Kin Tang; Emmanuel Scheubel; Joseph F Grippo; Sebastian A Moreira; Zenaida Go; James Mouskountakis; Theresa Louie; Prabha N Ibrahim; Harpreet Sandhu; Linda Rubia; Hitesh Chokshi; Dharmendra Singhal; Waseem Malick
Journal:  J Pharm Sci       Date:  2012-12-29       Impact factor: 3.534
  9 in total
  2 in total

Review 1.  Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine.

Authors:  Stefanie L Groenland; Ron H J Mathijssen; Jos H Beijnen; Alwin D R Huitema; Neeltje Steeghs
Journal:  Eur J Clin Pharmacol       Date:  2019-06-07       Impact factor: 2.953

Review 2.  Therapeutic drug monitoring of oral targeted antineoplastic drugs.

Authors:  Anna Mueller-Schoell; Stefanie L Groenland; Oliver Scherf-Clavel; Madelé van Dyk; Wilhelm Huisinga; Robin Michelet; Ulrich Jaehde; Neeltje Steeghs; Alwin D R Huitema; Charlotte Kloft
Journal:  Eur J Clin Pharmacol       Date:  2020-11-09       Impact factor: 2.953
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.